Literature DB >> 33761889

Deep learning assisted multi-omics integration for survival and drug-response prediction in breast cancer.

Vidhi Malik1, Yogesh Kalakoti1, Durai Sundar2.   

Abstract

BACKGROUND: Survival and drug response are two highly emphasized clinical outcomes in cancer research that directs the prognosis of a cancer patient. Here, we have proposed a late multi omics integrative framework that robustly quantifies survival and drug response for breast cancer patients with a focus on the relative predictive ability of available omics datatypes. Neighborhood component analysis (NCA), a supervised feature selection algorithm selected relevant features from multi-omics datasets retrieved from The Cancer Genome Atlas (TCGA) and Genomics of Drug Sensitivity in Cancer (GDSC) databases. A Neural network framework, fed with NCA selected features, was used to develop survival and drug response prediction models for breast cancer patients. The drug response framework used regression and unsupervised clustering (K-means) to segregate samples into responders and non-responders based on their predicted IC50 values (Z-score).
RESULTS: The survival prediction framework was highly effective in categorizing patients into risk subtypes with an accuracy of 94%. Compared to single-omics and early integration approaches, our drug response prediction models performed significantly better and were able to predict IC50 values (Z-score) with a mean square error (MSE) of 1.154 and an overall regression value of 0.92, showing a linear relationship between predicted and actual IC50 values.
CONCLUSION: The proposed omics integration strategy provides an effective way of extracting critical information from diverse omics data types enabling estimation of prognostic indicators. Such integrative models with high predictive power would have a significant impact and utility in precision oncology.

Entities:  

Keywords:  Deep learning; Feature selection; Multi-omics integration; Survival outcomes and drug response prediction

Mesh:

Substances:

Year:  2021        PMID: 33761889      PMCID: PMC7992339          DOI: 10.1186/s12864-021-07524-2

Source DB:  PubMed          Journal:  BMC Genomics        ISSN: 1471-2164            Impact factor:   3.969


  47 in total

1.  Chemosensitivity prediction by transcriptional profiling.

Authors:  J E Staunton; D K Slonim; H A Coller; P Tamayo; M J Angelo; J Park; U Scherf; J K Lee; W O Reinhold; J N Weinstein; J P Mesirov; E S Lander; T R Golub
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

2.  A gene expression database for the molecular pharmacology of cancer.

Authors:  U Scherf; D T Ross; M Waltham; L H Smith; J K Lee; L Tanabe; K W Kohn; W C Reinhold; T G Myers; D T Andrews; D A Scudiero; M B Eisen; E A Sausville; Y Pommier; D Botstein; P O Brown; J N Weinstein
Journal:  Nat Genet       Date:  2000-03       Impact factor: 38.330

3.  Precision Oncology beyond Targeted Therapy: Combining Omics Data with Machine Learning Matches the Majority of Cancer Cells to Effective Therapeutics.

Authors:  Michael Q Ding; Lujia Chen; Gregory F Cooper; Jonathan D Young; Xinghua Lu
Journal:  Mol Cancer Res       Date:  2017-11-13       Impact factor: 5.852

4.  A neural network model for survival data.

Authors:  D Faraggi; R Simon
Journal:  Stat Med       Date:  1995-01-15       Impact factor: 2.373

Review 5.  Mutant p53 in breast cancer: potential as a therapeutic target and biomarker.

Authors:  Michael J Duffy; Naoise C Synnott; John Crown
Journal:  Breast Cancer Res Treat       Date:  2018-03-21       Impact factor: 4.872

6.  Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer.

Authors:  Kumardeep Chaudhary; Olivier B Poirion; Liangqun Lu; Lana X Garmire
Journal:  Clin Cancer Res       Date:  2017-10-05       Impact factor: 12.531

7.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

8.  Anticancer drug sensitivity prediction in cell lines from baseline gene expression through recursive feature selection.

Authors:  Zuoli Dong; Naiqian Zhang; Chun Li; Haiyun Wang; Yun Fang; Jun Wang; Xiaoqi Zheng
Journal:  BMC Cancer       Date:  2015-06-30       Impact factor: 4.430

9.  A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer.

Authors:  Tanya T Kwan; Aditya Bardia; Laura M Spring; Anita Giobbie-Hurder; Mark Kalinich; Taronish Dubash; Tilak Sundaresan; Xin Hong; Joseph A LiCausi; Uyen Ho; Erin J Silva; Ben S Wittner; Lecia V Sequist; Ravi Kapur; David T Miyamoto; Mehmet Toner; Daniel A Haber; Shyamala Maheswaran
Journal:  Cancer Discov       Date:  2018-08-13       Impact factor: 39.397

10.  Comprehensive molecular portraits of human breast tumours.

Authors: 
Journal:  Nature       Date:  2012-09-23       Impact factor: 49.962

View more
  10 in total

1.  Leveraging Deep Learning Techniques and Integrated Omics Data for Tailored Treatment of Breast Cancer.

Authors:  Deeba Khan; Seema Shedole
Journal:  J Pers Med       Date:  2022-04-22

2.  Machine learning approach informs biology of cancer drug response.

Authors:  Eliot Y Zhu; Adam J Dupuy
Journal:  BMC Bioinformatics       Date:  2022-05-17       Impact factor: 3.307

3.  An overview of machine learning methods for monotherapy drug response prediction.

Authors:  Farzaneh Firoozbakht; Behnam Yousefi; Benno Schwikowski
Journal:  Brief Bioinform       Date:  2022-01-17       Impact factor: 11.622

4.  Multi-omics analysis identifies distinct subtypes with clinical relevance in lung adenocarcinoma harboring KEAP1/NFE2L2.

Authors:  Xiaodong Yang; Ming Li; Zhencong Chen; Xiaobin Fan; Liang Guo; Bo Jin; Yiwei Huang; Qun Wang; Liang Wu; Cheng Zhan
Journal:  J Cancer       Date:  2022-02-28       Impact factor: 4.207

Review 5.  Effectiveness of Artificial Intelligence for Personalized Medicine in Neoplasms: A Systematic Review.

Authors:  Sorayya Rezayi; Sharareh R Niakan Kalhori; Soheila Saeedi
Journal:  Biomed Res Int       Date:  2022-04-07       Impact factor: 3.246

Review 6.  Combining Molecular, Imaging, and Clinical Data Analysis for Predicting Cancer Prognosis.

Authors:  Barbara Lobato-Delgado; Blanca Priego-Torres; Daniel Sanchez-Morillo
Journal:  Cancers (Basel)       Date:  2022-06-30       Impact factor: 6.575

Review 7.  The Potential and Emerging Role of Quantitative Imaging Biomarkers for Cancer Characterization.

Authors:  Hishan Tharmaseelan; Alexander Hertel; Shereen Rennebaum; Dominik Nörenberg; Verena Haselmann; Stefan O Schoenberg; Matthias F Froelich
Journal:  Cancers (Basel)       Date:  2022-07-09       Impact factor: 6.575

Review 8.  Data integration and mechanistic modelling for breast cancer biology: Current state and future directions.

Authors:  Hanyi Mo; Rainer Breitling; Chiara Francavilla; Jean-Marc Schwartz
Journal:  Curr Opin Endocr Metab Res       Date:  2022-06

Review 9.  From Immunohistochemistry to New Digital Ecosystems: A State-of-the-Art Biomarker Review for Precision Breast Cancer Medicine.

Authors:  Sean M Hacking; Evgeny Yakirevich; Yihong Wang
Journal:  Cancers (Basel)       Date:  2022-07-17       Impact factor: 6.575

Review 10.  Angiogenesis goes computational - The future way forward to discover new angiogenic targets?

Authors:  Abhishek Subramanian; Pooya Zakeri; Mira Mousa; Halima Alnaqbi; Fatima Yousif Alshamsi; Leo Bettoni; Ernesto Damiani; Habiba Alsafar; Yvan Saeys; Peter Carmeliet
Journal:  Comput Struct Biotechnol J       Date:  2022-09-13       Impact factor: 6.155

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.